ArticleApoptosis : an international journal on programmed cell death2025
Ochratoxin A-induced mitochondrial pathway apoptosis and ferroptosis by promoting glycolysis.
Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Lactate-dependent regulation of ferroptosis: redox homeostasis, lactylation, and translational perspectives.Apoptosis : an international journal on programmed cell death · 2026Review
- Article
- Targeting lactylation in a novel metabolic-epigenetic-inflammatory axis mitigates inflammation and promotes healing following corneal injury.Journal of translational medicine · 2026Article
- Exposure to ochratoxin a induces organelle damage during porcine oocyte maturation.Frontiers in veterinary science · 2026Article
- Mycotoxin Contamination: Occurrence, Biotransformation, Pathogenic Mechanisms, and Strategies for Nutritional Intervention.Molecules (Basel, Switzerland) · 2025Review
- Agapanthussaponin A from the Underground Parts ofMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ochratoxin A (OTA), a toxic secondary metabolite recognized for its harmful effects on the kidneys, and it is commonly present in various foods and animal feeds. Although there have been few reports on the involvement of metabolic enzymes in OTA-induced nephrotoxicity and metabolic reprogramming in OTA-induced digestive tract toxicity, it remains unclear whether OTA's primary nephrotoxic effects are mediated through metabolic reprogramming. In this study, we examined the effects of OTA and/or 2-deoxy-D-glucose (2-DG) on cell viability, levels of reactive oxygen species (ROS), glutathione (GSH), malondialdehyde (MDA), and lactic acid (LA), as well as protein levels in human proximal tubule epithelial (HK-2) cells. The results indicate that OTA leads to a reduction in GSH levels and the protein levels of Lon protease 1 (Lonp1), tumor necrosis factor receptor-associated protein 1 (TRAP1), mitochondrial pyruvate carrier 1 (MPC1), glutathione peroxidase 4 (GPX4), B-cell lymphoma-2 (Bcl-2), and Bcl-2-like protein 1 (Bcl-xl), while increasing ROS, MDA, and LA levels, as well as the protein levels of glucose transporter type 1 (GLUT1), hexokinase 2 (HK2), pyruvate kinase 2 (PKM2), ATP-dependent 6-phosphofructokinase, platelet type (PFKP), long-chain fatty acid-CoA ligase 4 (ACSL4), Bcl-2-associated X protein (Bax), and cyclophilin D (CYPD) (P < 0.05). In conclusion, OTA induces mitochondrial pathway apoptosis and ferroptosis by disturbing mitochondrial homeostasis via the inhibition of Lonp1 and TRAP1, thereby reducing GSH levels, increasing ROS, MDA, and LA levels, and promoting glycolysis in vitro. This is the first report on OTA-induced mitochondrial pathway apoptosis and ferroptosis facilitated by mitochondrial homeostasis imbalance-mediated glycolysis in HK-2 cells.
Indexed as
Identifiers
40167953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.